Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott Marshall

Showing results (81-90 of 90) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 90 results.
British Journal of Haematology|May 26, 2020
Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML studyDragana Milojkovic, Nicholas C P Cross, Sahra Ali, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 9, 2020
Distributed learning on 20 000+ lung cancer patients - The Personal Health TrainTimo M Deist, Frank J W M Dankers, Priyanka Ojha, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 3, 2013
'Rapid Learning health care in oncology' - an approach towards decision support systems enabling customised radiotherapy'Philippe Lambin, Erik Roelofs, Bart Reymen, et al.
Clinical Pharmacology and Therapeutics|August 3, 2023
Model-Informed Drug Development: Steps Toward Harmonized GuidanceScott Marshall, Malidi Ahamadi, Jenny Chien, et al.
Haematologica|December 1, 2020
Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trialAndrew R Pettitt, Richard Jackson, Silvia Cicconi, et al.
Peerj|September 8, 2016
The health care and life sciences community profile for dataset descriptionsMichel Dumontier, Alasdair J G Gray, M Scott Marshall, et al.
Blood Advances|September 12, 2024
Outcomes with single-agent gilteritinib for relapsed or refractory FLT3-mutant AML after contemporary induction therapyJad Othman, Angela Hwang, Maximillian Brodermann, et al.
Blood|August 30, 2023
Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapyJad Othman, Ing S Tiong, Jenny O'Nions, et al.
Nature Communications|January 29, 2021
Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemiaWei-Yu Lin, Sarah E Fordham, Nicola Sunter, et al.
Journal of Biomedical Semantics|February 6, 2014
BioHackathon series in 2011 and 2012: penetration of ontology and linked data in life science domainsToshiaki Katayama, Mark D Wilkinson, Kiyoko F Aoki-Kinoshita, et al.
Pageof 9

Showing results (81-90 of 90) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
British Journal of Haematology|May 26, 2020
Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML studyDragana Milojkovic, Nicholas C P Cross, Sahra Ali, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 9, 2020
Distributed learning on 20 000+ lung cancer patients - The Personal Health TrainTimo M Deist, Frank J W M Dankers, Priyanka Ojha, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 3, 2013
'Rapid Learning health care in oncology' - an approach towards decision support systems enabling customised radiotherapy'Philippe Lambin, Erik Roelofs, Bart Reymen, et al.
Clinical Pharmacology and Therapeutics|August 3, 2023
Model-Informed Drug Development: Steps Toward Harmonized GuidanceScott Marshall, Malidi Ahamadi, Jenny Chien, et al.
Haematologica|December 1, 2020
Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trialAndrew R Pettitt, Richard Jackson, Silvia Cicconi, et al.
Peerj|September 8, 2016
The health care and life sciences community profile for dataset descriptionsMichel Dumontier, Alasdair J G Gray, M Scott Marshall, et al.
Blood Advances|September 12, 2024
Outcomes with single-agent gilteritinib for relapsed or refractory FLT3-mutant AML after contemporary induction therapyJad Othman, Angela Hwang, Maximillian Brodermann, et al.
Blood|August 30, 2023
Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapyJad Othman, Ing S Tiong, Jenny O'Nions, et al.
Nature Communications|January 29, 2021
Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemiaWei-Yu Lin, Sarah E Fordham, Nicola Sunter, et al.
Journal of Biomedical Semantics|February 6, 2014
BioHackathon series in 2011 and 2012: penetration of ontology and linked data in life science domainsToshiaki Katayama, Mark D Wilkinson, Kiyoko F Aoki-Kinoshita, et al.
Pageof 9